OncoMatch/Clinical Trials/NCT06235229
A Study of GC012F in Patients With Relapsed/Refractory Multiple Myeloma
Is NCT06235229 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies GC012F for multiple myeloma.
Treatment: GC012F — This study is a single-arm, open-lable, phase I/II study to evaluate the efficacy and safety of GC012F in subjects with relapsed/refractory multiple myeloma.
Check if I qualifyExtracted eligibility criteria
Cancer type
Multiple Myeloma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: proteasome inhibitor
Prior therapy should include proteasome inhibitors (PIs)
Must have received: immunomodulatory drug
Prior therapy should include immunomodulatory drugs (IMiDs)
Must have received: anti-CD38 antibody
Prior therapy should include anti-CD38 antibodies
Cannot have received: CAR-T cell therapy
Prior treatment with CAR-T products for any target
Cannot have received: allogeneic hematopoietic stem cell transplantation
Exception: Patients undergoing allo-HSCT who have discontinued all immunosuppressive drugs for 6 weeks prior to leukapheresis and have no manifestations of graft-versus-host disease (GVHD) may be enrolled.
Received an allogeneic hematopoietic stem cell transplantation (allo-HSCT) within 6 months prior to leukapheresis
Cannot have received: autologous hematopoietic stem cell transplantation
Received an autologous hematopoietic stem cell transplantation (auto-HSCT) within ≤ 12 weeks prior to leukapheresis
Lab requirements
Blood counts
Neutrophil count ≥ 0.75×10^9/L (growth factor support allowed, but not within 7 days prior to screening); Hemoglobin ≥ 8.0 g/dL (no red blood cell transfusion within 7 days prior to screening, recombinant human erythropoietin allowed); Platelet count ≥ 50×10^9/L (no platelet transfusion within 7 days prior to screening); Lymphocyte count ≥ 0.3×10^9/L
Kidney function
Creatinine clearance ≥ 40 mL/min, calculated by Cockcroft-Gault
Liver function
ALT/AST ≤ 3× ULN; Total bilirubin ≤ 2× ULN (Gilbert syndrome: direct bilirubin ≤ 1.5× ULN)
Cardiac function
LVEF ≥ 45% with no evidence of pericardial effusion as diagnosed by echocardiography; No clinically significant electrocardiogram abnormality observed
Adequate functional reserve of organs: ... see details
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify